In the always-thrilling biotech market, the act of shorting a stock, such as Cero Therapeutics, can often resemble an intricate dance. This process demands not only access to options trading or a broker willing to lend shares for short selling, but also a keen sense of timing and strategy. Whether an investor chooses to buy […]
Category: Myeloid Therapeutics
Phase 1 Trial of CER-1236 for Acute Myeloid Leukemia Update
CERo Therapeutics has achieved a significant landmark with the administration of the first dose to a patient in the Phase 1 trial of CER-1236 for Acute Myeloid Leukemia (AML). This progress puts the company on the leading edge of innovative therapeutics, targeting the unfulfilled medical requirements of patients grappling with this aggressive leukemia subtype. The […]
